Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.
Division of Cardiology, National Cardiovascular Center, Osaka, Japan.
Masafumi
M
Myoishi
Satoshi
S
Yasuda
Shunichi
S
Miyazaki
Kazuyuki
K
Ueno
Isao
I
Morii
Kazuhiro
K
Satomi
Yoritaka
Y
Otsuka
Atsushi
A
Kawamura
Takashi
T
Kurita
Shiro
S
Kamakura
Hiroshi
H
Nonogi
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003928:Diabetic Nephropathies / Q000150:complications / Q000628:therapy; D016903:Drug Monitoring; D004562:Electrocardiography; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant